Beta-Funaltrexamine Inactivates ORL1 Receptors in BE(2)-C Human Neuroblastoma Cells
Overview
Authors
Affiliations
The potential interactions of natively expressed mu-opioid and opioid receptor-like (ORL1) receptors were studied by exposing intact BE(2)-C cells to agonists or antagonists for 1 h. Pretreatment with the mu-opioid receptor agonist, [D-Ala(2), N-Me-Phe(4),Gly(5)-ol]enkephalin (DAMGO), or the ORL1 receptor agonist, orphanin FQ/nociceptin desensitized both mu-opioid and ORL1 receptor responses. beta-Funaltrexamine (beta-FNA) pretreatment also blocked both mu-opioid and ORL1 receptor responses, but only mu-opioid receptor binding was reduced. Moreover, beta-FNA (1 microM) failed to inhibit specific ORL1 receptor binding.
Differential Modulation of Ventral Tegmental Area Circuits by the Nociceptin/Orphanin FQ System.
Driscoll J, Wallace T, Mansourian K, Martin W, Margolis E eNeuro. 2020; 7(5).
PMID: 32747458 PMC: 7840174. DOI: 10.1523/ENEURO.0376-19.2020.
Lagard C, Chevillard L, Guillemyn K, Risede P, Laplanche J, Spetea M Pain. 2017; 158(3):505-515.
PMID: 28135212 PMC: 5302413. DOI: 10.1097/j.pain.0000000000000790.
Toll L, Bruchas M, Calo G, Cox B, Zaveri N Pharmacol Rev. 2016; 68(2):419-57.
PMID: 26956246 PMC: 4813427. DOI: 10.1124/pr.114.009209.
Pharmacological Profiles of Oligomerized μ-Opioid Receptors.
Lee C, Ho I Cells. 2014; 2(4):689-714.
PMID: 24709876 PMC: 3972655. DOI: 10.3390/cells2040689.
Donica C, Awwad H, Thakker D, Standifer K Mol Pharmacol. 2013; 83(5):907-18.
PMID: 23395957 PMC: 3629824. DOI: 10.1124/mol.112.084632.